A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(22 sites)
United States
Tucson Cystic Fibrosis Center, Tucson, Arizona Center for Cystic Fibrosis at Keck Medical Center of USC, Los Angeles, California Stanford University Medical Center, Palo Alto, California Augusta University, Augusta, Georgia The Cystic Fibrosis Institute, Northfield, Illinois Tulane University, New Orleans, Louisiana The Minnesota Cystic Fibrosis Center, Minneapolis, Minnesota Washington University School of Medicine, St Louis, Missouri Columbia University Cystic Fibrosis Program, New York, New York Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center, Cleveland, Ohio Nationwide Children's Hospital, Columbus, Ohio University of Pennsylvania, Philadelphia, Pennsylvania Dell Children's Medical Center of Central Texas, Austin, Texas Australia
Royal Prince Albert Hospital, Camperdown, New South Wales Westmead Hospital, Westmead, New South Wales Queensland Children's Hospital, Brisbane, Queensland The Prince Charles Hospital, Brisbane, Queensland Royal Adelaide Hospital, Adelaide, South Australia The Alfred Hospital, Melbourne, Victoria The Royal Children's Hospital, Parkville, Victoria Lung Institute of Western Australia, Nedlands, Western Australia The Kids Research Institute Australia, Perth Children's Hospital, Perth, Western Australia Last updated December 2025